tiprankstipranks
Advertisement
Advertisement
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
PremiumThe FlyOnKure Therapeutics downgraded to Hold from Buy at JonesResearch
3M ago
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target
Premium
Ratings
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target
3M ago
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
Premium
The Fly
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
3M ago
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
PremiumThe FlyOnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
5M ago
OnKure Therapeutics Advances Clinical Programs and Expands Focus
Premium
Company Announcements
OnKure Therapeutics Advances Clinical Programs and Expands Focus
9M ago
Promising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion
Premium
Ratings
Promising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion
9M ago
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
PremiumThe FlyOnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
9M ago
Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating
Premium
Ratings
Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating
10M ago
VTI ETF News, 10/9/2025
Premium
Market News
VTI ETF News, 10/9/2025
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100